Literature DB >> 16989096

Autonomic dysreflexia and telehealth.

Nathalie M Lapierre1, Jeff Blackmer, Ginette Coutu-Wakulczyk, Eric Dehoux.   

Abstract

With the rapid expansion of telehealth lines in the United States and the establishment of provincially funded lines in Canada, a growing number of people use this convenient approach to establish their initial health needs and to pursue self-care. Telehealth providers, for the most part, rely on electronic protocols to offer triaging and advice. Unfortunately, standard protocols are misleading when a premorbid health condition such as a spinal cord injury is present. Symptoms such as a headache, diaphoresis or an elevated blood pressure, which are common occurrences in the general population, may indicate an emergency situation, namely autonomic dysreflexia (AD), when a mid-thoracic and higher spinal cord lesion is present. Since there is no available electronic protocol on AD, this emergency health condition is not recognized by the telehealth provider and may put the caller at risk of serious morbidity or even death. In this article, the authors present the clinical features of AD, the precipitating factors and the nursing management of an episode. The merits and pitfalls of electronic protocols are reviewed and an algorithm is presented to assist telehealth providers in recognizing AD.

Entities:  

Mesh:

Year:  2006        PMID: 16989096

Source DB:  PubMed          Journal:  Can Nurse        ISSN: 0008-4581


  2 in total

Review 1.  What's happening now! Telehealth management of spinal cord injury/disorders.

Authors:  Christine Woo; Marylou Guihan; Christine Frick; Carol M Gill; Chester H Ho
Journal:  J Spinal Cord Med       Date:  2011       Impact factor: 1.985

2.  Evaluating knowledge of autonomic dysreflexia among individuals with spinal cord injury and their families.

Authors:  Colleen F McGillivray; Sander L Hitzig; B Cathy Craven; Mark I Tonack; Andrei V Krassioukov
Journal:  J Spinal Cord Med       Date:  2009       Impact factor: 1.985

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.